Identification of the Source of Elevated Hepatocyte Growth Factor Levels in Multiple Myeloma Patients

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2014 Apr 11

PMID 24716444

Citations 9

Authors

Christoph Rampa

Erming Tian

Thea Kristin Vatsveen

Glenn Buene

Tobias Schmidt Slordahl

Magne Borset

Anders Waage

Anders Sundan

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocyte growth factor (HGF) is a pleiotropic cytokine which can lead to cancer cell proliferation, migration and metastasis. In multiple myeloma (MM) patients it is an abundant component of the bone marrow. HGF levels are elevated in 50% of patients and associated with poor prognosis. Here we aim to investigate its source in myeloma.

Methods: HGF mRNA levels in bone marrow core biopsies from healthy individuals and myeloma patients were quantified by real-time PCR. HGF gene expression profiling in CD138+ cells isolated from bone marrow aspirates of healthy individuals and MM patients was performed by microarray analysis. HGF protein concentrations present in peripheral blood of MM patients were measured by enzyme-linked immunosorbent assay (ELISA). Cytogenetic status of CD138+ cells was determined by fluorescence in situ hybridization (FISH) and DNA sequencing of the HGF gene promoter. HGF secretion in co-cultures of human myeloma cell lines and bone marrow stromal cells was measured by ELISA.

Results: HGF gene expression profiling in both bone marrow core biopsies and CD138+ cells showed elevated HGF mRNA levels in myeloma patients. HGF mRNA levels in biopsies and in myeloma cells correlated. Quantification of HGF protein levels in serum also correlated with HGF mRNA levels in CD138+ cells from corresponding patients. Cytogenetic analysis showed myeloma cell clones with HGF copy numbers between 1 and 3 copies. There was no correlation between HGF copy number and HGF mRNA levels. Co-cultivation of the human myeloma cell lines ANBL-6 and JJN3 with bone marrow stromal cells or the HS-5 cell line resulted in a significant increase in secreted HGF.

Conclusions: We here show that in myeloma patients HGF is primarily produced by malignant plasma cells, and that HGF production by these cells might be supported by the bone marrow microenvironment. Considering the fact that elevated HGF serum and plasma levels predict poor prognosis, these findings are of particular importance for patients harbouring a myeloma clone which produces large amounts of HGF.

Citing Articles

A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and....

Knop S, Szarejko M, Grzasko N, Bringhen S, Trautmann-Grill K, Jurczyszyn A EJHaem. 2024; 5(5):940-950.

PMID: 39415900 PMC: 11474421. DOI: 10.1002/jha2.968.

The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma.

Giannoni P, de Totero D Cancer Drug Resist. 2022; 4(4):923-933.

PMID: 35582373 PMC: 8992445. DOI: 10.20517/cdr.2021.73.

Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.

Alvarez-Benayas J, Trasanidis N, Katsarou A, Ponnusamy K, Chaidos A, May P Nat Commun. 2021; 12(1):5450.

PMID: 34521827 PMC: 8440555. DOI: 10.1038/s41467-021-25704-2.

The HGF/Met/NF-κB Pathway Regulates RANKL Expression in Osteoblasts and Bone Marrow Stromal Cells.

Tsubaki M, Seki S, Takeda T, Chihara A, Arai Y, Morii Y Int J Mol Sci. 2020; 21(21).

PMID: 33114380 PMC: 7663721. DOI: 10.3390/ijms21217905.

Hepatocyte Growth Factor: A Microenvironmental Resource for Leukemic Cell Growth.

Giannoni P, Fais F, Cutrona G, de Totero D Int J Mol Sci. 2019; 20(2).

PMID: 30642077 PMC: 6359660. DOI: 10.3390/ijms20020292.

References

Seidel C, Borset M, Hjertner O, Cao D, Abildgaard N, Hjorth-Hansen H . High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood. 2000; 96(9):3139-46. View

Graziano F, Galluccio N, Lorenzini P, Ruzzo A, Canestrari E, DEmidio S . Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol. 2011; 29(36):4789-95. DOI: 10.1200/JCO.2011.36.7706. View

Borset M, Helseth E, Naume B, Waage A . Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation. Br J Haematol. 1993; 85(3):446-51. DOI: 10.1111/j.1365-2141.1993.tb03331.x. View

Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E . Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002; 99(5):1745-57. DOI: 10.1182/blood.v99.5.1745. View

Hjertner O, Hjorth-Hansen H, Borset M, Seidel C, Waage A, Sundan A . Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells. Blood. 2001; 97(2):516-22. DOI: 10.1182/blood.v97.2.516. View

Derksen P, de Gorter D, Meijer H, Bende R, van Dijk M, Lokhorst H . The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia. 2003; 17(4):764-74. DOI: 10.1038/sj.leu.2402875. View

Shaughnessy Jr J, Zhan F, Burington B, Huang Y, Colla S, Hanamura I . A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2006; 109(6):2276-84. DOI: 10.1182/blood-2006-07-038430. View

Borset M, Waage A, Brekke O, Helseth E . TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur J Haematol. 1994; 53(1):31-7. DOI: 10.1111/j.1600-0609.1994.tb00176.x. View

Phillip C, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V . Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2013; 6:92. PMC: 3878866. DOI: 10.1186/1756-8722-6-92. View

10.

Wader K, Fagerli U, Borset M, Lydersen S, Hov H, Sundan A . Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease. Histopathology. 2012; 60(3):443-51. DOI: 10.1111/j.1365-2559.2011.04112.x. View

11.

Yasui H, Hideshima T, Richardson P, Anderson K . Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol. 2006; 132(4):385-97. DOI: 10.1111/j.1365-2141.2005.05860.x. View

12.

Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A . Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem. 1996; 271(40):24655-61. DOI: 10.1074/jbc.271.40.24655. View

13.

Nilsson K, Bennich H, JOHANSSON S, Ponten J . Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol. 1970; 7(4):477-89. PMC: 1712861. View

14.

Derksen P, Keehnen R, Evers L, van Oers M, Spaargaren M, Pals S . Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood. 2002; 99(4):1405-10. DOI: 10.1182/blood.v99.4.1405. View

15.

Jackson N, Lowe J, Ball J, Bromidge E, LING N, Larkins S . Two new IgA1-kappa plasma cell leukaemia cell lines (JJN-1 & JJN-2) which proliferate in response to B cell stimulatory factor 2. Clin Exp Immunol. 1989; 75(1):93-9. PMC: 1541874. View

16.

Jelinek D, Ahmann G, Greipp P, Jalal S, Westendorf J, Katzmann J . Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res. 1993; 53(21):5320-7. View

17.

Hov H, Holt R, Ro T, Fagerli U, Hjorth-Hansen H, Baykov V . A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res. 2004; 10(19):6686-94. DOI: 10.1158/1078-0432.CCR-04-0874. View

18.

Zhan F, Huang Y, Colla S, Stewart J, Hanamura I, Gupta S . The molecular classification of multiple myeloma. Blood. 2006; 108(6):2020-8. PMC: 1895543. DOI: 10.1182/blood-2005-11-013458. View

19.

Roecklein B, Torok-Storb B . Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes. Blood. 1995; 85(4):997-1005. View

20.

Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E . Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol. 2002; 116(4):796-802. DOI: 10.1046/j.0007-1048.2002.03364.x. View